Arlington Capital Partners (Arlington), a private investment firm specialising in government regulated industries, has made a majority investment in Afton Scientific (Afton), a US contract, development and manufacturing organisation (CDMO) dedicated to sterile manufacturing of injectable pharmaceuticals.
Based in Charlottesville, Virginia, Afton specialises in sterile injectable drug manufacturing as well as providing pre-sterilised vials and kits. The company performs aseptic fill-finish for products ranging from pre-clinical through commercial-scale manufacturing across various therapeutic areas.
Tom Thorpe, Founder and CEO of Afton, will continue to lead the company and remain a material shareholder going forward.
Goodwin Procter served as legal advisor to Arlington. Bourne Partners served as financial advisor and Greenberg Traurig served as legal counsel to Afton in the transaction.
